Solid Biosciences Braces for Big Drop After DMD Data

SLDB stock is heavily shorted

Feb 7, 2019 at 9:19 AM
facebook twitter linkedin


Solid Biosciences Inc (NASDAQ:SLDB) could be on track for its worst day ever, after the life sciences company reported disappointing preliminary data for its Duchenne Muscular Dystrophy (DMD) gene therapy treatment. The study includes a planned dose escalation, and the company plans to move forward with a higher dosage.

In reaction to this early data, SLDB is bracing for a 72.9% drop this morning, and is set to open at an all-time low of $6.01 per share. If these pre-market losses hold, they would surpass the stock's 64.6% plunge on March 15 as Solid Biosciences' biggest one-day drop on record. Heading into today's trading, the equity was already down 16.6% year-to-date, and closed last night at $22.34.

One group of traders is cheering today's expected plunge. Short interest on SLDB jumped 23.2% in the two most recent reporting periods to a record 2.97 million shares. These bearish bettors will likely be sidelined until early next week, with the equity all but certain to land on the short-sale restricted list out of the gate.

Analysts have yet to weigh in on SLDB stock, but a round of bear notes could be on the horizon. Currently, three of six covering brokerages maintain a "strong buy" on the security, while the average 12-month priced target sits all the way up at $43.33.

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 

300x250 - Banner 3 - v1